Skip to main content
Home
  • facebook
  • twitter
  • linkedin
  • youtube
Home
  • Clinical Trials
  • Companies
  • Evidence Accelerator
  • Resources
    • Diagnostics
    • Medical News
    • Food
    • Veterinary

Clinical Trials and Expanded Access

Breadcrumb

  1. Home

Around the world, researchers are working extremely hard to develop new treatments and interventions for COVID-19 with new clinical trials opening nearly every day. This directory provides you with information, including enrollment detail, about these trials. In some cases, researchers are able to offer expanded access (sometimes called compassionate use) to an investigational drug when a patient cannot participate in a clinical trial.

The information provided here is drawn from ClinicalTrials.gov. If you do not find a satisfactory expanded access program here, please search in our COVID Company Directory. Some companies consider expanded access requests for single patients, even if they do not show an active expanded access listing in this database. Please contact the company directly to explore the possibility of expanded access.

Emergency INDs

To learn how to apply for expanded access, please visit our Guides designed to walk healthcare providers, patients and/or caregivers through the process of applying for expanded access. Please note that given the situation with COVID-19 and the need to move as fast as possible, many physicians are requesting expanded access for emergency use. In these cases, FDA will authorize treatment by telephone and treatment can start immediately. For more details, consult FDA guidance. Emergency IND is the common route that patients are receiving convalescent plasma.

Search Tips

To search this directory, simply type a drug name, condition, company name, location, or other term of your choice into the search bar and click SEARCH. For broadest results, type the terms without quotation marks; to narrow your search to an exact match, put your terms in quotation marks (e.g., “acute respiratory distress syndrome” or “ARDS”). You may opt to further streamline your search by using the Status of the study and Intervention Type options. Simply click one or more of those boxes to refine your search.

Displaying 5 of 5

London School of Hygiene and Tropical Medicine

Coronavirus Response - Active Support for Hospitalised Covid-19 Patients

Conditions: COVID-19

The CRASH-19 trial is a multinational, open-label, factorial, randomised trial in adults hospitalised with suspected or confirmed acute COVID-19 infection.

Gilead Sciences

Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)

Conditions: SARS-CoV2 Infection

The primary objective of this study is to provide expanded access of remdesivir (RDV) for the treatment of severe acute respiratory syndrome coronavirus (SARS-CoV2) infection.

RedHill Biopharma Limited

Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen

Conditions: COVID-19, Lung Infection

Patients diagnosed with COVID-19 infection will be offered treatment with Opaganib, 500 mg Q12 hours. Opaganib will be continuously administered for up to 2 weeks, until discharged on room air (if earlier than 2 weeks).

ClinAmygate

Growth Hormone in Obese Cases With Covid-19

Conditions: COVID19

The use of growth hormone in obese cases with COVID-19 may help them to recover earlier.

Eli Lilly and Company, AbCellera Biologics Inc.

Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19

Conditions: COVID-19

The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

Status

  • Recruiting (2648)
  • Not yet recruiting (1128)
  • Active, not recruiting (479)
  • Enrolling by invitation (176)
  • Completed (30)
  • Expanded Access (26)
  • Suspended (3)
  • (-) Withdrawn (3)
  • (-) Approved for marketing (1)
  • (-) No longer available (1)
  • Terminated (1)

Intervention Type

  • Drug (5)

Subscribe for updates from the Reagan-Udall Foundation for the FDA

Subscribe
(202) 849 - 2075
1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036
admin@reaganudall.org
  • facebook
  • twitter
  • linkedin
  • youtube

© Reagan-Udall Foundation for the FDA
© Reagan-Udall Foundation for the FDA